Loading

Clinical trials

Clinical Trials

Clinical trials available at CBS Clinic

 

1. BREAST: TRIO-US B-12 TALENT -A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of trastuzumab deruxtecan (DS-8201a) with or without anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting –https://clinicaltrials.gov/ct2/show/NCT04553770

2. LUNG: Canopy-ACZ885-A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) –https://clinicaltrials.gov/ct2/show/NCT03447769

3. BREAST/KIDNEY: Infinity IPI-549-03- Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma –https://clinicaltrials.gov/ct2/show/NCT03961698

4. LUNG: Mirati: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE) –https://clinicaltrials.gov/ct2/show/NCT03906071

5. BREAST: Novartis EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation –https://clinicaltrials.gov/ct2/show/NCT04478266

6. BREAST: Sanofi EFC15935: A randomized, multicenter, double-blind Phase 3 study of amcenestrant (SAR439859) plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease –https://clinicaltrials.gov/ct2/show/NCT04478266

7. BREAST: lidERA: PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN’S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER –https://clinicaltrials.gov/ct2/show/NCT04961996

8. BREAST: Roche: persevERA Breast Cancer: A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer –https://clinicaltrials.gov/ct2/show/NCT04546009

9. BREAST: Lilly: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (MONARCH plus) –https://clinicaltrials.gov/ct2/show/NCT02763566

10. LYMPHOMA: orphoSys AG – MOR208C310, A phase 3, multicenter, randomized, double blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) (Pro00047422) –https://www.clinicaltrials.gov/ct2/show/NCT04824092

11. LUNG/MELANOMA/HER2 cancer: Merk: Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001) –https://clinicaltrials.gov/ct2/show/NCT01295827

12. HER2 cancers: Molecular Templates, Inc Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) –https://clinicaltrials.gov/ct2/show/NCT04029922

13.BREAST/LUNG: Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as  Adjunctive Oncology Treatment-https://clinicaltrials.gov/ct2/show/NCT04862195